Ensuring Efficiency in Pharmaceutical Expenditures

This chapter examines options for ensuring good value for money in pharmaceutical expenditure, keeping in mind both the short- and the long-term view. It then discusses the scope for improvement to existing policies and emerging alternative approaches.

[1]  E. Docteur,et al.  Pharmaceutical Pricing and Reimbursement Policies in Canada , 2007 .

[2]  E. Docteur,et al.  Pharmaceutical Pricing and Reimbursement Policies in Germany , 2008 .

[3]  W. Brouwer,et al.  A dollar is a dollar is a dollar--or is it? , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  W. Manning,et al.  The demand for prescription drugs as a function of cost-sharing. , 1985, Social science & medicine.

[5]  M. Drummond,et al.  Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Trevor A Sheldon,et al.  What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews , 2004, BMJ : British Medical Journal.

[7]  M. Dickson,et al.  Survey of Pharmacoeconomic Assessment Activity in Eleven Countries , 2003 .

[8]  E. Docteur,et al.  Pharmaceutical Pricing and Reimbursement Policies in Mexico , 2007 .

[9]  A. Guionnet,et al.  La sécurité sociale , 1989 .

[10]  J. Lexchin,et al.  Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence , 2004, International journal of health services : planning, administration, evaluation.

[11]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  J. Puig-Junoy.  What is required to evaluate the impact of pharmaceutical reference pricing? , 2005, Applied health economics and health policy.

[13]  J. Vernon,et al.  Mathematical Modeling and Pharmaceutical Pricing: Analyses Used to Inform In-Licensing and Developmental Go/No-Go Decisions , 2005, Health care management science.

[14]  E. Docteur,et al.  Pharmaceutical Pricing and Reimbursement Policies in Sweden , 2007 .

[15]  John Nixon,et al.  Can economic evaluations be made more transferable? , 2005, The European Journal of Health Economics.

[16]  F. Knaul,et al.  Evidence is good for your health system: policy reform to remedy catastrophic and impoverishing health spending in Mexico , 2006, The Lancet.

[17]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[18]  J A Hanley,et al.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons. , 2001, JAMA.

[19]  Steve Morgan,et al.  The Common Drug Review: a NICE start for Canada? , 2006, Health policy.

[20]  E. Docteur,et al.  OECD HEALTH WORKING PAPERS Pharmaceutical Pricing and Reimbursement Policies in Mexico , 2007 .

[21]  T. Walley,et al.  Financial incentives and prescribing , 2004 .

[22]  E. Docteur,et al.  Pharmaceutical Pricing and Reimbursement Policies in Switzerland , 2007 .